The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The phase II study of efficacy and safety of oxaliplatin with doxorubicin in recurrent ovarian cancer (OC).
I. Pokataev
No relevant relationships to disclose
G. M. Manikhas
No relevant relationships to disclose
V. Borisov
No relevant relationships to disclose
M. Stenina
No relevant relationships to disclose
A. Tjulandina
No relevant relationships to disclose
S. Tjulandin
No relevant relationships to disclose